BNTC
NASDAQ HealthcareBenitec Biopharma Inc. - Common Stock
Biotechnology
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
�� 市场数据
| 价格 | $11.02 |
|---|---|
| 成交量 | 422,989 |
| 市值 | 384.41M |
| 贝塔系数 | 0.270 |
| RSI（14日） | 35.2 |
| 200日均线 | $12.05 |
| 50日均线 | $12.47 |
| 52周最高 | $16.76 |
| 52周最低 | $9.85 |
| Forward P/E | -1.17 |
| Price / Book | 2.14 |
🎯 投资策略评分
BNTC 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (69/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🐋 Institutional Whale (12/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 BNTC in your text
粘贴任何文章、记录或帖子 — 工具将提取 BNTC 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-09-18.